These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

561 related items for PubMed ID: 27487144

  • 1. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM, Koochekpour S.
    Oncotarget; 2016 Sep 27; 7(39):64447-64470. PubMed ID: 27487144
    [Abstract] [Full Text] [Related]

  • 2. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.
    Eur Urol; 2015 Mar 27; 67(3):470-9. PubMed ID: 25306226
    [Abstract] [Full Text] [Related]

  • 3. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.
    Cancer Lett; 2017 Jul 01; 397():133-143. PubMed ID: 28323036
    [Abstract] [Full Text] [Related]

  • 4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA, Yen AE, Weigel NL.
    Pharmacol Ther; 2013 Dec 01; 140(3):223-38. PubMed ID: 23859952
    [Abstract] [Full Text] [Related]

  • 5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb 01; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S, Hashemy SI, Sahebkar A, Aghaee Bakhtiari SH.
    Curr Mol Pharmacol; 2021 Oct 25; 14(4):559-569. PubMed ID: 33357209
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C, Abboud K.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118
    [Abstract] [Full Text] [Related]

  • 11. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ, Milowsky MI, Whang YE.
    Clin Pharmacol Ther; 2015 Dec 22; 98(6):582-9. PubMed ID: 26331358
    [Abstract] [Full Text] [Related]

  • 12. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
    Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C.
    Oncotarget; 2017 Jan 24; 8(4):6796-6808. PubMed ID: 28036278
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.
    Cancer Lett; 2016 Aug 28; 379(1):154-60. PubMed ID: 27233475
    [Abstract] [Full Text] [Related]

  • 15. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug 28; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

  • 16. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
    Ho Y, Dehm SM.
    Endocrinology; 2017 Jun 01; 158(6):1533-1542. PubMed ID: 28368512
    [Abstract] [Full Text] [Related]

  • 17. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
    Karantanos T, Corn PG, Thompson TC.
    Oncogene; 2013 Dec 05; 32(49):5501-11. PubMed ID: 23752182
    [Abstract] [Full Text] [Related]

  • 18. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
    Alhawas L, Amin KS, Salla B, Banerjee PP.
    Carcinogenesis; 2021 Apr 17; 42(3):423-435. PubMed ID: 33185682
    [Abstract] [Full Text] [Related]

  • 19. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
    Katzenwadel A, Wolf P.
    Cancer Lett; 2015 Oct 10; 367(1):12-7. PubMed ID: 26185001
    [Abstract] [Full Text] [Related]

  • 20. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, Chen X, Jiang XS, McCall SJ, Inman BA, Huang J.
    Eur Urol; 2022 May 10; 81(5):446-455. PubMed ID: 35058087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.